Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. by Valacchi, G & Bocci, V
Studies on the biological effects of
ozone: 10. Release of factors from
ozonated human platelets
G. Valacchi and Velio Bocci
CA
Institute of General Physiology, University of Siena,
53100 Siena Italy
CACorresponding Author
Tel: (+39) 577 234217
Fax: (+39) 39 577 234219
Email: fisgen@unisi.it
IN a previous work we have shown that heparin, in
the presence of ozone (O3), promotes a dose-depend-
ent  platelet  aggregation,  while  after  Ca2+ chelation
with citrate, platelet aggregation is almost negligible.
These  results  led  us  to  think  that  aggregation  may
enhance the release of platelet components. We have
here shown that indeed significantly higher amount
of platelet-derived growth factor (PDGF), transform-
ing growth factor b 1 (TGF-b 1) and interleukin-8(IL-8)
are released in a dose-dependent manner after ozona-
tion  of  heparinised  platelet-rich  plasma  samples.
These findings may explain the enhanced healing of
torpid ulcers in patients with chronic limb ischemia
treated with O3 autohaemoteraphy (O3-AHT).
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Introduction
Ozone (O3) can promote platelet aggregation partic-
ularly when heparin is used as an anticoagulant1: this
observation is not surprising in the light of previous
results2 showing the role of reactive oxygen species
(ROS) in platelet activation. In  contrast, Ca2+ chela-
tion with citrate markedly inhibits aggregation.1Thus,
the selection  of the most appropriate anticoagulant
becomes crucial when blood is intended to be used
for  autotransfusion  (O3-AHT)  after  being  briefly
exposed  to  a  gas  mixture  composed  of  about  97%
oxygen and 3% ozone.3 It is known that platelets are
a  rich  source  of  several  growth  factors  such  as
platelet-derived growth factor (PDGF),4 transforming
growth  factor  b 1  (TGF-b 1),5 eicosanoids  and  inter-
leukins (IL).6
PDGF and TGFb 1 promote wound healing and if, in
the course of O3AHT, the reinfused platelets increase
their  release,  it  can  be  envisaged  how  this  com-
plementary therapy, besides improving oxygenation
of hypoxic tissues, enhances healing of torpid ulcers
in  chronic  limb  ischemia.  For  this  reason  we  have
now  investigated  whether  the  use  of  heparin  or
citrate added to blood, before ozonation, affects the
release of platelet factors differently.
Materials and methods
Ozone generation and measurement
O3 was  generated  from  medical  grade  O2 using
electrical corona arc discharge in the last generation
O3 generator  (Model  Ozonosan  PM100K,  Hansler
GmbH,  Iffezheim,  Germany)  which  allows  the  gas
flow rate and O3 concentration  to be controlled in
real time by photometric determination at 253.7nm
as recommended by the Standardisation  Committee
of the International O3 Association.
Reagents
Anticoagulants  were  either  heparin  (calcium  salt,
30IU/ml  blood)  normally  used  for  therapeutic  pur-
poses (Calciparina,  Italfarmaco) or ACD (Citric acid,
Na  citrate,  Glucose) (Haemonetics, Braintree,  USA).
Adenosine  diphosphate  (ADP)  was  a  product  from
Sigma  Chemical  Co.  (St.  Louis,  Mo)  and  for  the
studying  aggregation  a  0.5mM  solution  was  freshly
prepared.
Preparation of platelet rich plasma (PRP)
samples
Both ACD and heparinised platelet rich plasma (PRP)
were prepared from the same blood samples (60ml)
drawn, after informed consent, from five fasting (12
hours) non-smokers volunteers between the ages of
23 and 27 years, who were considered to be healthy
and had not ingested platelet-active medication for at
least two weeks.
Nine parts blood were anticoagulated with either
one part ACD or with one part of saline containing
heparin so that its final concentration was 30IU/ml.
Blood  was  centrifuged  at  200  3 g  for  20min  and
platelets were measured with a Coulter counter. An
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used. A further centrifugation of PRP at 6000 3 g for
15sec gave a  platelet-containing pellet and a super-
natant  platelet-free  plasma  used  for  biochemical
determinations.
O2 and O3 delivery to biological samples
A predetermined volume of the O2/O3 gas mixture at
three O3 concentrations (20, 40 and 80 m g/ml per ml
of PRP) was collected with a silicone coated dispos-
able  syringe  and  immediately  introduced  into  a
second  syringe  containing  an  equivalent  volume  of
PRP via a ‘y’ connector. Final gas pressure remained at
normal  atmospheric  pressure.  In  order  to  obtain
reproducible results, it needs to be emphasised that
O3 is a very reactive gas so that extremely rapid and
precise handling is required. The PRP samples were
gently but continuously mixed with the gas for up to
30sec and afterwards they were dispensed into test
tubes  for  various  analysis.  Control  samples  were
either untreated or mixed with an equal volume of
O2. After  incubation  each  sample  was  immediately
centrifuged at 10,000 3 g for 20min at 2°C and the
supernatant  platelet-free plasma was used for deter-
mining  variations  of  thiobarbituric  acid  reactive
substances  (TBARS),7 the  total  antioxidant  status
(TAS)8 and of protein thiol groups (PTG) according to
Hu.9 An aliquot of the plasma samples was frozen at
–70°C until  determinations of several  factors speci-
fied below were carried out.
Biochemical determinations
1. Thiobarbituric  acid  reactive  substances  (TBARS)
determination: in order to evaluate the relevance
of lipid peroxidation, TBARS were assessed accord-
ing to Pompella et al.7
2. Total  antioxidant  status  (TAS) in  plasma  samples
was assessed according to Rice-Evans and Miller.8
3. Protein  thiol  groups  (PTG)  were  measured  in
plasma according to Hu9 using procedure 1 with
5,59 -Dithio-bis(2-Nitrobenzoic  acid)  DTNB  dis-
solved in absolute methanol.
Immunoassay
Immunoassays  of  either  human  PDGF-AB  or TGFb 1
(after activation of the latent TGFb 1 to the immunor-
eactive  form)  were  carried  out  using  Quantikine
immunoassay kits produced by R&D System (Minnea-
polis,  USA).  On  the  basis  of  preliminary  tests  hep-
arinised  PRPs  were  diluted  1:20 while  citrate  PRPs
were diluted 1:1 only. Possible release of thrombox-
ane A2,  a  vasoconstrictor  and  aggregation-enhancer
factor, was monitored by measuring the stable com-
pound  thromboxane B2  (TXB2) by using an  immu-
noassay kit produced by R&D Systems. For this assay,
plasma samples were diluted 1:5. Immunoassay of IL-
8 was carried out using Cytoscreen kit produced by
Biosource International (Camarillo, CA, USA). Plasma
samples  were  diluted  1:1  with  the  appropriate
diluent. A  3-cycle  automatic  washing  was  routinely
performed.  Samples  have  been  tested  at  least  in
duplicate against the appropriate standards.
Statistical analysis
Results  obtained  from  five  donors  have  been
expressed as the mean ± the standard deviation of the
mean  (SD). A  software  package  was  used  for  data
collection and statistical analysis (Statview SE, Abacus
Concepts Inc., Berkeley, California). The significance
of  the  differences  between  the  means  at  different
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FIG. 1. Effect of 30sec exposure of either O2 or O2–O3 (20, 40
and 80m g/ml perml of plasma) on total antioxidant status
(TAS),  protein  thiol  group  (PTG)  and  thiobarbituric  acid
reactive substances (TBARS) of the same human platelet rich
plasma samples collected either in heparin or in ACD. The
statistical  significance  has  been  indicated  with  a  (*)  for
intergroup and with a (+) for intragroup analysis.Effects of ozone on platelets
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FIG. 2. Release of factors from human platelets during 1, 2 and 4h incubation. The same PRP samples collected either in
heparin or ACD were either not exposed (control), or exposed to O2 alone, or O2–O3 at 20, 40 and 80m g/ml concentration for
30sec before incubation. The statistical significance has been indicated with a (*) for intergroup and with a (+) for intragroup
analysis.times in each group was analysed by one-way analysis
of variance (ANOVA). The significance of the differ-
ences between means for the two groups at different
times  was  analysed  by  Student’s  t-test. The  level  of
statistical significance was set at p<0.05 for both inter
and intragroups analysis.
Results
Particularly  PTG  values  decreased  in  approximate
relation  with  the  O3 concentration  while  TBARS
values  increased  several  folds  (Fig.1). Moreover  we
have observed that oxidation of PTG is far higher in
heparinised  that  Ca2+ chelated  samples  suggesting
that  physiological  Ca2+ levels  favour  ROS  activity.
Indeed intragroup analysis showed a significant differ-
ence at a medium (40 m g/ml) and at a high (80m g/ml)
O3 concentration.
Fig.2 shows the strikingly and significant different
release of PDGF AB, TGFb 1 and IL-8 from heparinised
in comparison to Ca2+ chelated PRP samples. For the
first two cytokines the difference is clear at all times,
while for IL-8 it becomes evident only after 4 hours of
incubation. As far as the release of TXB2 is concerned,
heparin does not appear to have a determinant  role
and  both  anticoagulants  have  yielded  significant
differences after ozonation of PRPs.
Discussion
A  modified  form  of AHT,  by  irradiating  blood  with
ultraviolet light, was firstly proposed by Wehrli  and
Steinbart10 but AHT became popular after Wolff11 had
shown that direct exposure of blood to a known dose
of O2–O3 was very simple, practical and free of risk of
contamination.  Since  that  time,  countless  O3-AHT
sessions have been performed in Europe and in spite
of a lack of double-blind, randomised studies, it seems
that this approach can be useful in vascular diseases,
particularly in  chronic limb ischemia. Rokitansky et
al12 and Werkmeister13 had shown that even at late
stages  (III  and  IV  grade)  of  the  disease,  O3-AHT,
combined  to  topic  application  of  ozone,  can  spare
amputation  and  favour  healing of torpid  ulcers and
necrotic  areas.  It  is  unfortunate  that  the  results  of
these studies have been reported in a rather anecdotal
form, so that during a revision 14–15 of this field, it was
pointed  out  that  not  only  it  is  urgent  to  perform
controlled studies but  to clearly  understand  mecha-
nisms of  action  and  explain  why O3-AHT enhances
healing of ulcers.
A first important point that has never been clarified
was  which  type  of  anti-coagulant:  heparin  or  the
usual sodium citrate would be more suitable. Indeed
in a previous work1, we have shown that heparin, in
the presence of O3, can promote platelet aggregation
while, in contrast, Ca2+ chelation is practically ineffec-
tive.  We  then  went  to  suspect  that  promotion  of
aggregation would favour  the release of an array  of
intracellular  components  from  platelets  and  we
thought  worth  while  to  carry  out  a  preliminary
investigation.
We have now shown  that  two  important  healing
factors, namely PDGF and TGFb 1, increase markedly
during  incubation  particularly  in  heparinised  PRP
samples exposed  to 40 and  80 m g/ml of O3. If this
happens in vivo, after reinfusion of ozonated blood in
patients with  chronic limb  ischemia,  it  may indeed
favour  healing  of  necrotic  ulcers.  However,  this
assumption  must  be  tempered  by  the  previous
finding1 that  platelet  aggregation  corresponds  to
either 20±6% or as much as 68±14% for O3 concentra-
tions  of  either  40  or  80 m g/ml,  respectively.  The
former O3 concentration still does allow an important
release  of  growth  factors  with  no  risk  of  blood
coagulation and therefore may represent the optimal
O3 concentration.
The fairly late release of IL-8 has been interpreted as
due to the time lag necessary for the synthesis. It is
known  that  induction  of  IL-8  by  O3,  while  is
promoted  by  a  temporary  rise  of  H2O2
14–16 in
cytoplasmic water via the activation of nuclear factor
(NF)-kB,  is  inhibited  by  ROS  scavengers.17 As  this
chemokine  is  capable  of  initiating  the  chemotactic
gradient that draws leukocytes from circulation into
tissues, it may exert the additional role of favouring
phagocytosis of bacteria and necrotic tissue present
in torpid ulcers.
Release of TXB2, as the stable compound derived
from thromboxane A2, appears as a drawback but we
cannot  draw  a  conclusion  unless  we  carry  out
determination  of  other  eicosanoids  such  as  prosta-
glandin E2 and prostacyclin that induce vasodilation
and  inhibit  aggregation.  By  using  endothelial  cells,
work now in progress aims to clarify the role of O3
activation  of  cyclooxygenase  and  nitric  oxide
syntethase.
On  the  basis  of  these  results,  we  would  like  to
evaluate  comparatively  the  effectiveness  of AHT  in
patients  with  chronic  limb  ischemia  treated  with
either citrated or heparinised blood exposed to the
mild O3-AHT concentration of 40 m g/ml.
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